ecancer

The paediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups

Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany

30 May 2020

COVID-19: Managing paediatric patients under the COVID pandemic

Dr Carmen Ballestas - Memorial Healthcare System, Florida, Miami

4 May 2020

Updates in treating NTRK fusion cancer: Highlights from ESMO 2019

Prof Marc Peeters and Prof Jesus Garcia-Foncillas

9 Mar 2020

Indian Pediatric Oncology Group (InPOG)

Dr. Ramandeep Arora - Max Institute of Cancer Care, Saket, New Delhi, India

20 Feb 2020

Outcomes in paediatric oncology: Are we closing the gap between LMICs and high-income countries?

Prof Laila Hessissen - Mohammed V University of Rabat, Rabat, Morocco

7 Feb 2020

CAR-T cell therapy for ALL: Current challenges and future approaches

Dr Sara Ghorashian - University College London, London, UK

23 Jan 2020

CART-T cell therapy in young patients with relapsed/refractory ALL

Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany

$CART-T cell therapy in young patients with relapsed/refractory ALL ( Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany )$

23 Jan 2020

The role of blinatumomab followed by HSCT in paediatric patients with ALL

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

23 Jan 2020

Long-term toxicities in paediatric ALL

Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark

23 Jan 2020

Frontline therapy of ALL

Prof Hervé Dombret - University Paris Diderot, Paris, France

23 Jan 2020

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL

Prof Hervé Dombret - University Paris Diderot, Paris, France

23 Jan 2020

Identifying cancer susceptibility genes in paediatric ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA

23 Jan 2020

More from ecancer